Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer.
about
Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta roleCirculating Tumor Cell and Cell-free Circulating Tumor DNA in Lung CancerCirculating tumor cells versus circulating tumor DNA in lung cancer-which one will win?Detection of rare point mutation via allele-specific amplification in emulsion PCR.Genetic variant rs401681 at 5p15.33 modifies susceptibility to lung cancer but not esophageal squamous cell carcinomaCombination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers.Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites.Benzo[a]pyrene decreases global and gene specific DNA methylation during zebrafish developmentThe Prognostic Value of Circulating Cell-Free DNA in Colorectal Cancer: A Meta-AnalysisCirculating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted SequencingNew strategy for monitoring targeted therapy: molecular imaging.Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.Update on biomarkers for the detection of lung cancer.Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer.Liquid Biopsy in Non-Small Cell Lung Cancer.Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.Circulating free DNA in the progression of liver damage to hepatocellular carcinoma.Cell-free DNA as a prognostic marker in stage I non-small-cell lung cancer patients undergoing stereotactic body radiotherapy.Plasma cell-free DNA and survival in non-small-cell lung cancer: A meta-analysisNew insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA.Incorporating Blood-based Liquid Biopsy Information into Cancer Staging: Time for a TNMB System?Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?Utility of urinary circulating tumor DNA for EGFR mutation detection in different stages of non-small cell lung cancer patients.Quantification of circulating cell-free DNA to predict patient survival in non-small-cell lung cancer.Cell-Free DNA Quantification and Methylation Status of DCC Gene as Predictive Diagnostic Biomarkers of Lung Cancer in Patients Reported at Gulab Devi Chest Hospital, Lahore.Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients.Predictive value of circulating cell-free DNA in the survival of breast cancer patients: A systemic review and meta-analysisCirculating cell-free DNA: a potential biomarker in lung cancerRole of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer
P2860
Q26769734-EFF5CC6B-F365-432D-B430-874D7955B665Q28067582-0795F149-8AD0-4E9E-9F51-C3BDA189CC4DQ28077340-A075B9A4-1514-43EE-86A6-91621547CBF6Q34049474-44A5577A-B63C-479B-A22F-CEB4A06C2592Q35080890-4C60AC59-92C1-4219-B748-AFA9FA1BE561Q35964716-6B14BAB0-32B6-480F-9C02-DE2DFEB76480Q36384490-FF20DE2C-756F-4D1E-A106-1A4249430584Q36639217-10F2C21E-EFE0-4B4F-9E83-1B74F5DBD5A6Q36844184-9EE880B6-54A6-4546-9672-8F945001678DQ37015727-5268C3BD-031A-4430-85A3-2862745B6A79Q37198902-04780C5A-EC31-4766-81AE-8B32B589D3E1Q37225316-9832E070-F700-40AC-9B38-FC33EABCAA15Q37536958-A9A40573-9414-4BB1-9EE0-5024F1002C50Q37645219-30FA77D5-0C0F-48CA-B763-C8FAEBA9E9D5Q38263419-11BF13D3-2F6C-41BB-ADBE-5F787085EBB8Q39076207-049BB5AA-3644-4065-A9E4-3E5C2A8B05EDQ39106800-82F87AF6-85D8-4418-847C-23829D2F6E2BQ40206402-7CA33E5F-3CA9-49AB-AF9A-94DD6FBBEF2FQ40706725-3565FFD9-3745-4D09-B023-485550C2CA5FQ41157591-5CBA5EF2-0A6E-4110-A9FC-041DABC9E853Q41162179-DED30491-BC15-4B20-8270-2CC457EB8BA8Q47159366-B3159DD2-011C-48D6-8784-B7BF8DA8400EQ47563363-CD587DCF-F8CE-4665-92BF-9975E22A0B88Q47883536-58D4CEAA-254B-4FBB-89D2-1AFA15B7C667Q47893937-F0BF0B33-A200-411F-8415-6F71EF501B63Q49217100-C0824FC2-DDC6-4D8B-A987-BAEB361ED9D2Q50088187-5567D38D-F5A8-4AD3-8258-9E808E84AD9BQ54300832-48F00917-2F82-4FF9-AA3C-018D53624D57Q57110507-972C2804-6ECB-4A1C-A3AE-FDFEC8C27AC2Q57306273-D03B5505-F154-4F24-A372-253CC2009FFBQ59233182-5888BBFD-ED84-4F27-AA2A-1AC52A3FA74C
P2860
Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Circulating DNA is a useful pr ...... ed non-small cell lung cancer.
@en
Circulating DNA is a useful pr ...... ed non-small cell lung cancer.
@nl
type
label
Circulating DNA is a useful pr ...... ed non-small cell lung cancer.
@en
Circulating DNA is a useful pr ...... ed non-small cell lung cancer.
@nl
prefLabel
Circulating DNA is a useful pr ...... ed non-small cell lung cancer.
@en
Circulating DNA is a useful pr ...... ed non-small cell lung cancer.
@nl
P2093
P50
P1476
Circulating DNA is a useful pr ...... ed non-small cell lung cancer.
@en
P2093
Ana Blasco
Andrea Cabrera
José Galbis
José Javier Sánchez
Nieves Del Pozo
Ricardo Guijarro
Roy M Bremnes
P304
P356
10.1097/JTO.0B013E31820189A5
P577
2011-02-01T00:00:00Z